Through a multi‐pronged strategy to modulate immune cells including the maturation of DCs through ICD by Toy‐mediated ERS amplification for subsequent activation of tumor‐infiltrating CD4+ and CD8+ T cells and reduction of Tregs in tumors, Au NPs‐mediated M2‐type TAM repolarization, and Anti‐PD‐L1‐mediated ICB therapy for further activation of T cells, enhanced chemoimmunotherapy of pancreatic tumor model can be realized under the assistance of UTMD. The gene discussed is CD8A; the disease is neoplasm.